Q3 2025 Biomx Inc Earnings Call Transcript

Nov 12, 2025 / 01:30 PM GMT

Release Date Price: $7.15 (-1.88%)

Transcript 10-Q8-K

Key Points

Positve

BiomX Inc (PHGE) achieved a significant milestone by dosing the first patient in their phase 2B trial for BX004, targeting cystic fibrosis patients with pseudomonas infections.
The FDA provided constructive feedback on BX004, recognizing the unmet need for treatments targeting chronic pseudomonas infections in cystic fibrosis patients.
European trials for BX004 continue uninterrupted, as the nebulizer components are CE marked in Europe.
Positive FDA feedback was received for BX011, targeting Staphylococcus aureus infection in diabetic foot infections, supporting the development strategy.
BiomX Inc (PHGE) has a clear regulatory pathway for BX011, with no additional non-clinical studies required, aligning with FDA guidance for diabetic foot infection product development.

Negative

The FDA placed a clinical hold on US trial sites for BX004 due to issues with a third-party nebulizer device, causing a temporary pause in US enrollment.
BiomX Inc (PHGE) reported a decrease in cash balance from $18 million at the end of 2024 to $8.1 million as of September 30, 2025, primarily due to net cash used in operating activities.
Net loss for the third quarter of 2025 was $9.2 million, a significant decrease from a net income of $9.6 million in the third quarter of 2024.
Research and development expenses decreased due to workforce reduction and lower rent expenses, indicating potential cost-cutting measures.
The company's cash reserves are only sufficient to fund operations into the first quarter of 2026, indicating potential financial constraints.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PHGE.A - Biomx Inc
Q3 2025 Biomx Inc Earnings Call
Nov 12, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to Bomics 3rd quarter 2025 financial results and program update conference call.

Currently, all participants are in a listen-only mode.

At the end of this call, there will be a question-and-answer session.

As a reminder, this conference call is being recorded.

I would now like to turn the call over to Marina Wolfson, Chief Financial Officer of Bomics. Please.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Proceed.

Thank you and welcome to the Bionics conference call to review the company's 3rd quarter, 2025 financial results and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.